Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Estudio sobre LY3473329 en adultos con trastorno de lipoproteínas y ...
LY3473329 for Kidney Function Clinical Trial 2024 | Power
Muvalaplin (LY3473329) | Lipoprotein (a) inhibitor | Probechem Biochemicals
Nature：发现脂蛋白(a)形成的强效小分子抑制剂 - 每日生物评论
Discovery and preclinical development of LY3473329, a potent small ...
Muvalaplin | TargetMol
#muvalaplin #ly3473329 #lp #lipoprotein #pelacarsen #olpasiran… | Min W.
Muvalaplin|LY3473329——药研档案
RCSB PDB - 8V8Z: Lipoprotein(a) Kringle IV domain 8 - Lp(a) KIV8 in ...
Muvalaplin(LY3473329) | CAS 2565656-70-2 | Selleck
May 2025 Patent Highlights: LP(a) inhibitor from CSPC is better?
Muvalaplin (LY3473329) | Lp (a) Inhibitor | MedChemExpress
(LY-3473329)-药物靶点：lipoprotein(a)_在研适应症：动脉粥样硬化，心血管疾病，高脂蛋白血症_专利_临床_研发
Muvalaplin tetrahydrochloride (LY3473329 tetrahydrochloride) | Lp (a ...
New Lp(a) lowering drug - Rapamycin Longevity News
Muvalaplin (LY3473329) | Lp(a)抑制剂 | MCE
多价策略制胜！礼来全球首个Lp(a)小分子设计思路深度剖析医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Muvalaplin tetrahydrochloride | TargetMol
Discovery of potent small-molecule inhibitors of lipoprotein(a ...
ChemGood
Muvalaplin | Drug Information, Uses, Side Effects, Chemistry ...
文献解析|脂蛋白(a)形成高效小分子抑制剂的发现、机制及临床前疗效
降脂蛋白a药物Muvalaplin（LY3473329）治疗脂蛋白a（Lp(a)）升高_水平_apo_事件
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus ...
KRAKEN Trial Highlights Muvalaplin’s Efficacy, Safety in Reducing ...
Oral Muvalaplin effectively lowers lipoprotein (a) with no serious ...
礼来全球首创口服Lp(a)抑制剂拟纳入突破性疗法医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
6000万美元预付款：礼来引进Verve临床前项目，靶向Lp(a)体内基因编辑疗法 Armstrong 2023年6月15日，Verve ...
New Lipoprotein(a) Treatments: Lp(a) Pipeline and Clinical Trials - GoodRx
Current and future treatment options - Medizinonline
Nature里程碑：礼来揭秘首款降低Lp(a)水平小分子药物，已进入II期临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Muvalaplin Found to Significantly Lower Lipoprotein(a) Levels, Offering ...
Eli Lilly presents the preclinical profile of LY-3473329 | BioWorld
穆伐普林(Muvalaplin) - 药物靶点：Lp(a)_在研适应症：外周动脉疾病，动脉粥样硬化_专利_临床_研发
Muvalaplina, um novo inibidor oral da formação de lipoproteína (a ...
New insights into the therapeutic options to lower lipoprotein(a ...
VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May ...
「新药进展速递」礼来全球首创口服Lp(a)抑制剂拟纳入突破性疗法 - 今日头条
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a ...
Muvalaplin Significantly Lowers Lipoprotein(a) in Adults With High Risk ...
Practical Fragments
Eli Lilly Announces Positive Phase 2 Results for Muvalaplin, Oral ...
lipoprotein (a) drug, Muvalaplin, clears phase II clinical trials ...
MUVALAPLIN: IL PRIMO FARMACO ORALE ANTI-LIPOPROTEINA (A) | Giuseppe ...
降脂药市场新风口：Lp(a)靶向药物研发成MNC竞逐焦点_药智新闻
Muvalaplin | C42H54N4O6 | CID 155369486 - PubChem
Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in ...
礼来降低脂蛋白(a)口服药物muvalaplin 2期临床研究公布积极结果医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Muvalaplin in high-risk patients (KRAKEN, NCT05563246, Completed) - Lp ...
如何选择合适的小分子抑制剂？ - 知乎
First Drug Shown to Lower Lp(a) in Heart Attack Prevention (Muvalaplin ...
JAMA：世界首个口服药，心脏病标志物水平降低65%-MedSci.cn
LDLR | 低密度脂蛋白受体 | 抑制剂 | MCE
Update on lipid lowering therapies: Muvalaplin - Lp(a) Forum
首款针对「坏胆固醇」的口服药问世，这对相关疾病患者来说意味着什么？ - 知乎
(A) Molecular modeling of vigabatrin bound to show that Lys-329 is not ...
A structure–activity relationship study of the positive allosteric ...
“减肥神药”减少心衰症状？—新闻—科学网
Muvalaplin | 莫伐倍林 | TargetMol
MUVALAPLIN
Thuốc mới làm giảm thành công mức cholesterol Lp(a) - ASEAN News - Tạp ...
LY345899 ≥95% (HPLC) | Sigma-Aldrich
LY3310756 HCl | C28H32F3N5O4S2 | CID 126644142 - PubChem
A novel, competitive mGlu5 receptor antagonist (LY344545) blocks DHPG ...
A-935142 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Chemical structures of Mv3glc, Me-py, vitisin A, and oxovitisin ...
